A Form 4 filed on August 26, 2026 reports that Adam Taich, Chief Financial Officer of 10x Genomics, Inc. (NASDAQ:TXG), disposed of 17,166 shares of Class A Common Stock on August 24, 2026 to cover tax withholding obligations tied to the vesting of restricted stock units.

Key Highlights

  • Reporting Person: Adam Taich, Chief Financial Officer of 10x Genomics, Inc.
  • Shares Disposed: 17,166 shares of Class A Common Stock sold on August 24, 2026
  • Weighted Average Price: $63.023 per share, with individual trades ranging from $63.0088 to $63.73
  • Purpose: Shares were sold to cover tax withholding obligations in connection with RSU vesting, according to the filing
  • Remaining Ownership: 362,732 shares of Class A Common Stock directly held following the transaction
  • Transaction Code: S (sale), filed as a non-derivative securities transaction

10x Genomics CFO RSU Vesting Triggers Tax-Related Share Sale

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Adam Taich, the Chief Financial Officer of 10x Genomics, Inc., disposed of 17,166 shares of Class A Common Stock on August 24, 2026. The filing states that the shares were sold specifically to cover tax withholding obligations arising from the vesting of restricted stock units, a common mechanism used by companies to satisfy tax liabilities at the time equity awards vest.

The filing discloses that the transaction was executed across multiple trades at prices ranging from $63.0088 to $63.73, inclusive. The reported price of $63.023 represents the weighted average sale price across those trades. The filing notes that Taich, through his attorney-in-fact Randy Wu, undertakes to provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer, or a security holder.

Following the reported transaction, Taich directly beneficially owns 362,732 shares of Class A Common Stock in 10x Genomics, Inc., according to the filing. No derivative securities transactions were reported in Table II of the Form 4. The form was signed by Randy Wu as attorney-in-fact for Adam Taich and dated August 26, 2026.

What Was Disclosed

The filing discloses a single sale transaction by 10x Genomics CFO Adam Taich on August 24, 2026, covering 17,166 shares of Class A Common Stock at a weighted average price of $63.023, made to satisfy tax withholding requirements on vested restricted stock units.